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(n=560)
CABG
(n=280)
P
value
1-month outcomes
MACE (death, MI, revascularization) 13.4% 15.4% 0.46
NACE (death, MI, revascularization, and major
bleeding)
19.1% 17.5% 0.45
All-Cause Mortality 2.1% 3.6% 0.22
Myocardial Infarction 10.2% 12.7% 0.33
Unplanned Revascularization 4.3% 1.4% 0.03*
Stroke 0.2% 0.7% 0.26
1-year outcomes
MACE 22.4% 19.7% 0.49
Death or MI 15.4% 16.4% 0.65
All-Cause Mortality 4.3% 4.7% 0.72
MI 12.7% 13.1% 0.88
Unplanned Revascularization 12.7% 5.2% 0.001*
TLR 8.5% n/a
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Sincreased mortality, irrespective of the presentation. Substantial patients with STEMI
experience no chest pain and are given a low priority score at the triage of emergency
department. We aimed to determine the impact of non-chest pain complaint
as a presenting symptom on the DTB time and clinical outcomes in patients with
STEMI.
Methods: A total of 11,417 STEMI patients who underwent primary PCI were
derived from the Korea Working Group on Myocardial Infarction from 2005 to 2012
and compared according to typical chest pain or non-chest pain complaint as a pre-
senting symptom. The primary outcomes were 12-month mortality and the composite
of major adverse cardiac events (MACE, deﬁned as death, non-fatal myocardial
infarction, and revascularization).
Results: Compared to patients with typical chest pain (n¼9,948, 87.1%), patients
with non-chest pain complaint (n¼1,469, 12.9%) were older, more female, and had
higher incidence of hypertension and diabetes, and also had higher incidence of
anterior infarct and higher Killip class. The time delay was also signiﬁcant in door-
to-laboratory arrival time (53 vs. 64 min, p<0.001), laboratory arrival-to-balloon
(20 vs. 23 min, p<0.001), and the DTB time (75 vs. 89 min, p<0.001). Non-chest
pain complaint was an independent determinant of the DTB time both in adjusted
models and in multivariate linear regression analysis. Patients with non-chest pain
complaint had more in-hospital death (4.1% vs. 11.5%, p<0.001), 12-month
mortality (6.5% vs. 16.3%, p<0.001), and the composite of MACE (12.2% vs.
22.5%, p<0.001).
Conclusions: The delays in identiﬁcation of STEMI and reperfusion treatment were
greater and associated with worse clinical outcomes in patients with non-chest pain
complaint as a presenting symptom. A triage using electrocardiogram should be
considered in these patients.Heparin + GPI
N=1532
Bivalirudin alone
N=1611 p value
30-days
Mortality 0.9% 1.5% 0.14
MI 5.8% 7.2% 0.0958
Urgent TVR 2.4% 2.1% 0.5720
NACE 13.5% 12.6% 0.4482
Composite ischemic outcome 8.2% 9.3% 0.3001
Non-CABG major bleeding 7.1% 4.1% 0.0002
1-year
Mortality 4.0% 3.8% 0.8293
Composite ischemic outcomes 17.4% 19.0% 0.0629TCT-260
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Background: Proximal LAD (pLAD) lesions are associated with increased cardio-
vascular risk in the setting of acute coronary syndrome (ACS). Surgical versus
percutaneous revascularization improves outcomes including mortality in complex
stable CAD. However, the impact of different revascularization strategies in ACS
patients with pLAD lesions remains unknown.
Methods: We performed a post-hoc analysis of patients in the ACUITY trial
(n¼13,819) presenting with a critical stenosis of the pLAD who underwent subse-
quent revascularization with a surgical or percutaneous approach (PCI). Major adverse
events comprised of death, myocardial infarction, repeat revascularization, stroke, and
bleeding were compared at 30 days and 1-year.
Results: Among the 842 patients we studied, revascularization was performed with
PCI and coronary artery bypass grafting (CABG) in n¼562 (67%) and n¼280 (33%)
respectively. Baseline clinical and angiographic characteristics were well balanced
between groups. Patients in the CABG group were more likely to undergo angiog-
raphy later than PCI (median time ﬁrst drug-angiography, 43 vs. 4 hours, P<0.01).
PCI was associated with an increase rate of revascularization at 1 month and 1 year,
without signiﬁcant difference in other clinical endpoints (Table 1).
Conclusions: Although surgical revascularization of proximal LAD during ACS
reduces further revascularization, it does not seem to improve the survival and MI
rates at 1-year compared with PCI.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-261
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Background: There are limited data on the effects of bivalirudin monotherapy
compared to standard antithrombotic therapy (heparin plus glycoprotein IIb/IIIa
inhibitor – GPI) on the outcomes of higher –risk acute coronary syndromes
(ACS) patients with positive biomarkers on admission. We examined the clin-
ical outcomes among positive biomarker patients undergoing percutaneous
coronary intervention (PCI) in the large-scale prospective, randomized ACUITY
trial.
Methods: The ACUITY trial was a multicenter, randomized trial assessing the
safety and efﬁcacy of bivalirudin alone or bivalirudin plus GPI vs. heparin plus
GPI among 13,819 patients with moderate and high-risk ACS, 7,789 of
whom underwent PCI. The in-hospital and 30-days primary endpoints were
composite ischemia (death, MI, or unplanned TVR for ischemia), Non-CABG
major bleeding, and net adverse clinical events (NACE¼composite ischemia or
major bleeding).
Results: A total of 4,728 PCI patients presented with a positive biomarker at the time
of admission. Of those, 1,532 were randomized to heparin plus GPI and 1,611 to
bivalirudin alone. There were no relevant baseline differences between treatment
groups regarding clinical proﬁle, TIMI risk score, antiplatelet medications and DES
use. Outcomes by treatment group at 30-days and 1-year are shown in the table. In
a multivariate model, use of bivalirudin was not a predictor of composite ischemic
outcomes up to one year (hazard ratio [95% CI]¼1.12 [0.97, 1.29], p¼0.1239), but
was associated with a reduction in major bleeding.acts/POSTER/STEMI/NSTEMI/ACS B85
